Hemodynamic response to coupled plasmafiltration-adsorption in human septic shock

Objective: The objective was to examine the effect of repeated applications of coupled plasmafiltration-adsorption on the hemodynamic response in septic shock patients hospitalized in intensive care units (ICUs). Design: Prospective, intention-to-treat. Setting: General ICU of a tertiary care, non-teaching, 400-bed, city hospital. Patients and participants: Twelve consecutive mechanically ventilated septic shock patients, with or without concomitant acute renal failure (ARF). Intervention: A median of 10 consecutive sessions (prescribed treatment time: 10 h/session; delivered duration: 8.43+/-1.37 h/min) of coupled plasmafiltration-adsorption for each patient. Measurements and results: Mean arterial pressure (77.2+/-12.5 [CI 95%; 74.5-79.8] vs. 83.3+/-14.1 [CI 95%; 80.3-86.3] mm Hg; [p<0.001]), cardiac index (4.03+/-0.89 [CI 95%; 3.83-4.22] vs. 3.46+/-0.82 [CI 95%; 3.28-3.64] L/m(2)/min; [p<0.001]), systemic vascular resistance index (1,388 496 [CI 95%; 1,278-1,497] vs. 1,753 516 [CI 95%; 1,639-1,867] dynes x s/cm(5); [p<0.001]), P02/FI02 ratio (204 87 [CI 95%; 185-223] vs. 238 82 [CI 95%; 220-256]; [p<0.001]), significantly improved during 100 global treatments (pre- vs. post-treatment values). Intra-thoracic blood volume and extra-vascular lung water did not change across treatments. Vasopressor requirement was reduced: norepinephrine decrease from an infusion rate of 0.13+/-0.07 (CI 95%; 0.06-0.16) to 0 gamma/kg/min after a mean of 5.3+/-2.7 sessions. C reactive protein (CRP) significantly decreased (from 29.3+/-7.3 vs. 7.9+/-4.8; p<0.0001) during treatment. Survival was 90% at day 28 and 70% at day 90. Conclusion: Coupled plasmafiltration-adsorption was a feasible and safe extracorporeal treatment and exerted a remarkable improvement in the hemodynamics, the pulmonary function, and the outcome in septic shock patients with or without concomitant ARF.